Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue
November 13, 2008 08:10 ET
|
Novogen, Limited
NEW CANAAN, CT--(Marketwire - November 13, 2008) - The Independent Data Monitoring Committee
(IDMC) constituted to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial,...
Independent Data Monitoring Committee Recommends Marshall Edwards, Inc.'s OVATURE Trial Continue
November 12, 2008 08:10 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - November 12, 2008) - The Independent Data Monitoring Committee
(IDMC) constituted to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial,...
Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination
October 30, 2008 19:19 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies
presented at the 9th International Conference on Membrane Redox Systems in
Wellington New Zealand this...
Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers
April 13, 2008 16:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at
the annual meeting of the American Association for Cancer Research
demonstrate that Marshall Edwards,...
Phenoxodiol Trials Highlighted at Ovarian Cancer Action International Conference
March 10, 2008 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of
the investigational drug phenoxodiol in restoration of chemosensitivity in
ovarian cancer patients...
Additional Orphan Drug Status Granted for Melanoma for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)
February 19, 2008 07:31 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - February 19, 2008) - Marshall Edwards, Inc., (NASDAQ: MSHL)
announced today that triphendiol (previously known as NV-196) has been
granted Orphan Drug status by the U.S....
Orphan Drug Status Granted for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)
January 22, 2008 08:54 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 22, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced today that its triphendiol (previously known as NV-196) has been
granted orphan drug status by the...
Novogen NV-128 Induces Novel Mode of Cell Death in Cancer Cells
October 24, 2007 08:07 ET
|
Novogen
SAN FRANCISCO, CA--(Marketwire - October 24, 2007) - Laboratory studies presented late
yesterday at the annual AACR/EORTC/NCI Molecular Targets and Cancer
Therapeutics conference demonstrate that...
New Data on Novogen Oncology Pipeline to Be Released
October 23, 2007 08:05 ET
|
Novogen
SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - October 23, 2007) - New data on the
Novogen oncology pipeline compound NV-128 will be presented on October 23
at the annual AACR/EORTC/NCI...
Yale Cancer Center Sponsors Study of Phenoxodiol for Prostate Cancer
October 22, 2007 19:25 ET
|
Marshall Edwards, Inc.
NEW HAVEN, CT--(Marketwire - October 22, 2007) - Yale researchers have begun recruiting 60 men
for a clinical trial investigating an experimental new drug, oral
phenoxodiol, as a potential first line...